Harbour BioMed (HKEX: 02142), a global biopharmaceutical company specializing in novel antibody therapeutics for immunology and oncology, has announced the launch of Élancé Therapeutics. The new venture aims to address challenges in current obesity treatments, such as muscle preservation and long-term efficacy.
Obesity affects nearly one billion people worldwide and is linked to serious health complications. Current treatments often have limitations, including lean mass loss and post-treatment weight regain. Élancé plans to develop bispecific antibody therapies that improve weight loss outcomes while preserving lean muscle mass. These therapies aim to complement existing treatments, including agonists of GLP-1 receptor, GIP receptor, and GCG receptor.
The company's pipeline includes multiple bispecific antibody programs in pre-clinical development, focusing on targeted hormone modulation and enhanced metabolic regulation. Élancé will also refine and expand Nona Biosciences' Hu-mAtrIx AI platform to support antibody discovery, utilizing AI for antibody sequence optimization and patient biomarker studies.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze